Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31074613 | 0.82 | SMN1; SMN2 (0.34) | L3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL31074664 | 0.82 | GRM2 (0.36) | GRM2HDAC1HDAC6HDAC5 | |
| SCHEMBL31074527 | 0.81 | MEN1 (0.39) | L3MBTL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL31074615 | 0.80 | L3MBTL1 (0.34) | L3MBTL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL31074719 | 0.79 | SMN1; SMN2 (0.34) | L3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL31074655 | 0.79 | SMN1; SMN2 (0.34) | L3MBTL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL31074561 | 0.79 | SMN1; SMN2 (0.34) | L3MBTL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL31074598 | 0.79 | SMN1; SMN2 (0.34) | L3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL31074571 | 0.79 | SMN1; SMN2 (0.43) | L3MBTL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL31074473 | 0.78 | SMN1; SMN2 (0.37) | MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665734-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| US-20240360137-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | NOVARTIS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| WO-2024171094-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | NOVARTIS AG (CH) | 2024-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360137-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | CDK2, CDK1, CCNK | GRM2 2607/4885HDAC1 629/4885HDAC6 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.